NCT02536625View on ClinicalTrials.gov

Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

December 31, 2019

Conditions

Breast Cancer

Interventions

OTHER

prospective study

Trial Locations (2)

69008

Centre Leon Berard, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

All Listed Sponsors

collaborator

The Biostatistics and Therapy Evaluation Unit

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Ligue contre le cancer, France

OTHER

lead

Centre Leon Berard

OTHER

NCT02536625 - Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative) | Biotech Hunter | Biotech Hunter